Literature DB >> 10564299

The pathophysiology of pulmonary hypertension in congenital heart disease.

R H Steinhorn1, J R Fineman.   

Abstract

Congenital heart disease with increased pulmonary blood flow commonly leads to the development of pulmonary hypertension and increased vascular reactivity. These serious sequelae are associated with the following two major categories of congenital heart defects: those resulting in increased pulmonary blood flow and increased pulmonary arterial pressure and those resulting in increased pulmonary venous pressure. Recent evidence that the pulmonary vascular endothelium is an important determinant of vascular tone has led to the hypothesis that endothelial injury, secondary to congenital heart disease with increased pulmonary blood flow, disrupts these regulatory mechanisms and thereby plays a role in the development of pulmonary hypertension and its associated increased vascular reactivity. In many animal models, endothelial dysfunction is a precursor for smooth muscle dysfunction, and there is an apparent progression from endothelial dysfunction to smooth muscle dysfunction as vascular changes progress. We established a chronic model of pulmonary hypertension with increased pulmonary blood flow in young lambs by placing a systemic-to-pulmonary shunt in utero. In this model, we found significant physiologic and molecular alternations of both the nitric oxide (NO) and endothelin signaling pathways, two important mechanisms by which the endothelium regulates pulmonary vascular tone. These alterations occur extremely early and precede severe anatomic changes. Early endothelial damage may contribute to the development of pulmonary hypertension and its associated enhanced pulmonary vascular reactivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564299     DOI: 10.1046/j.1525-1594.1999.06447.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  9 in total

Review 1.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

2.  Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling.

Authors:  Namasivayam Ambalavanan; Arlene Bulger; Joanne Murphy-Ullrich; Suzanne Oparil; Yiu-Fai Chen
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

3.  Genetic variation in the mitochondrial enzyme carbamyl-phosphate synthetase I predisposes children to increased pulmonary artery pressure following surgical repair of congenital heart defects: a validated genetic association study.

Authors:  Jeffrey A Canter; Marshall L Summar; Heidi B Smith; Geraldine D Rice; Lynn D Hall; Marylyn D Ritchie; Alison A Motsinger; Karla G Christian; Davis C Drinkwater; Frank G Scholl; Karrie L Dyer; Ann L Kavanaugh-McHugh; Frederick E Barr
Journal:  Mitochondrion       Date:  2006-11-29       Impact factor: 4.160

4.  Successful treatment of chronic thromboembolic pulmonary hypertension with inhaled nitric oxide after right ventricular thrombectomy.

Authors:  Kiyoaki Takaba; Masaki Aota; Michihito Nonaka; Akihiro Sugimoto; Yutaka Konishi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-05

5.  Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung.

Authors:  Namasivayam Ambalavanan; Teodora Nicola; James Hagood; Arlene Bulger; Rosa Serra; Joanne Murphy-Ullrich; Suzanne Oparil; Yiu-Fai Chen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-16       Impact factor: 5.464

6.  Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions.

Authors:  Namasivayam Ambalavanan; Teodora Nicola; Peng Li; Arlene Bulger; Joanne Murphy-Ullrich; Suzanne Oparil; Yiu-Fai Chen
Journal:  Pediatr Res       Date:  2008-01       Impact factor: 3.756

7.  Endothelin-1 mediates hypoxia-induced increases in vascular collagen in the newborn mouse lung.

Authors:  Namasivayam Ambalavanan; Peng Li; Arlene Bulger; Joanne Murphy-Ullrich; Suzanne Oparil; Yiu-Fai Chen
Journal:  Pediatr Res       Date:  2007-05       Impact factor: 3.756

8.  Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases.

Authors:  Xi Zhang; Hai-Tao Hou; Jun Wang; Xiao-Cheng Liu; Qin Yang; Guo-Wei He
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

9.  Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension.

Authors:  Xiao-Ye Li; Yu Zheng; Yuliang Long; Xiaochun Zhang; Lei Zhang; Dan Tian; Daxin Zhou; Qian-Zhou Lv
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-09       Impact factor: 2.557

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.